This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oliveira, M.
Right arrow Articles by Wainberg, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oliveira, M.
Right arrow Articles by Wainberg, M. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2009, p. 1683-1685, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01168-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations{triangledown}

Maureen Oliveira,1 Daniela Moisi,1 Bonnie Spira,1 Susan Cox,2* Bluma G. Brenner,1 and Mark A. Wainberg1

McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Côte-Ste-Catherine Road, Montreal, Quebec QC H3T 1E2, Canada,1 Avexa Ltd., 576 Swan Street, Richmond, Victoria 3121, Australia2

Received 1 September 2008/ Returned for modification 17 October 2008/ Accepted 30 January 2009

Human immunodeficiency virus type 1 containing the reverse transcriptase mutation M184V or K65R or mutations M41L, M184V, and T215Y did not accumulate additional resistance mutations in the reverse transcriptase when increasing amounts of apricitabine drug pressure were applied. The original mutations were maintained by the presence of apricitabine but were lost when cultured without drug pressure.

* Corresponding author. Mailing address: 576 Swan St., Richmond, Victoria 3121, Australia. Phone: 61 3 9208 4300. Fax: 61 3 9208 4004. E-mail: scox{at}avexa.com.au

{triangledown} Published ahead of print on 17 February 2009.

Antimicrobial Agents and Chemotherapy, April 2009, p. 1683-1685, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01168-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gaffney, M. M, Belliveau, P. P, Spooner, L. M (2009). Apricitabine: A Nucleoside Reverse Transcriptase Inhibitor for HIV Infection. The Annals of Pharmacotherapy 43: 1676-1683 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»